Ligand Pharmaceuticals LGND Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's financing cash flow?
- Ligand Pharmaceuticals (LGND) reported financing cash flow of -$14.13M in Q1 2026.
- How has Ligand Pharmaceuticals's financing cash flow changed year-over-year?
- Ligand Pharmaceuticals's financing cash flow decreased by 197.7% year-over-year, from -$4.75M to -$14.13M.
- What is the long-term trend for Ligand Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Ligand Pharmaceuticals's financing cash flow has grown at a 44.5% compound annual growth rate (CAGR), from -$141.93M to $428.22M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.